NCT00836069 - Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

April 30, 2010

Conditions

Anxiety Disorders

Interventions

DRUG

No drug name provided by Sponsor; drug referenced as PD 0332334

Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.

DRUG

Paroxetine

FDA Approved medication for generalized anxiety disorder, oral tablet, at 20mg, once daily for 8 weeks and then 2 weeks of dose tapering.

DRUG

Placebo

inactive substance, oral tablet, once per day, for 10 weeks.

Trial Locations (1)

90048

Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences, Los Angeles